Table 1.
Pt ID | Sorted abnormal cell population | TCR-Vβ+ | Vβ gene identified | PCR+ | CD4:CD8 ratio | CD4+CD7−, % | CD4+CD26−, % | Stage |
---|---|---|---|---|---|---|---|---|
1 | CD3+CD4+CD7−CD26− | Yes | 20 | Yes | 8.37 | 19.7 | 14.1 | B1 |
2 | CD3+CD4+CD26− | Yes | 2 | Yes | 179.0 | 8.6 | 80.2 | B2 |
3 | CD3+CD4+CD26− | Yes | 12 | Yes | 2.12 | 8.9 | 34.3 | B2 |
4 | CD3+CD4+CD7−CD26− | Yes | Indirect | No | 8.11 | 14.3 | 38.5 | B2 |
5 | CD3+CD4+CD26− | Yes | 16 | Yes | 15.6 | 10 | 71.5 | B2 |
6 | CD3+CD4+CD7−CD26− | Yes | 1 | Yes | 28.69 | 86.2 | 84.5 | B2 |
7 | CD3+CD4+CD7−CD26− | Yes | 13.6 | None | 56.81 | 83.9 | 58.7 | B2 |
8 | CD3+CD4+CD7−CD26− | Yes | 12 | Yes | 24.78 | 54.9 | 71.4 | B2 |
9 | CD3+CD4+CD7−CD26− | N/A | N/A | Yes | 10.22 | 38.9 | 36.5 | B2 |
10 | CD3+CD4+CD7−CD26− | Yes | 13.1 | Yes | 7.06 | 44.3 | 25.5 | B2 |
11 | CD3+CD4+CD26− | Yes | 13.6 | Yes | 9.66 | 11.4 | 46 | B2 |
12 | CD3+CD4+CD26− | Yes | Indirect | Yes | 5.18 | 1.9 | 48.5 | B2 |
13 | CD3+CD4+CD7−CD26− | Yes | 21.3 | Yes | 59.63 | 89.8 | 88.7 | B2 |
14 | CD3+CD4+CD26− | No | None | Yes | 4.45 | 16.2 | 4.8 | B1 |
15 | CD3+CD4+CD7−CD26− | Yes | Indirect | Yes | 6.95 | 63.9 | 62.6 | B2 |
16 | CD3+CD4+CD7−CD26− | Yes | Indirect | Yes | 20.02 | 87.2 | 76.3 | B2 |
17 | CD3+CD4+CD7−CD26− | Yes | 7.2 | Yes | 4.7 | 30.4 | 33.8 | B2 |
18 | CD3+CD4+CD7−CD26− | Yes | 7.2 | Yes | 3.74 | 27.4 | 26.0 | B1 |
19 | CD3+CD4+CD7−CD26− | No | None | No | 1.21 | 20.6 | 22.5 | B1 |
20 | CD3+CD4+CD7−CD26− | Suspicion | Indirect | Yes | 1.63 | 22.5 | 24.5 | B1 |
21 | CD3+CD4+CD7−CD26− | Suspicion | 5.3 | None | 4.75 | 69.6 | 71.8 | B2 |
22 | CD3+CD4+CD7−CD26− | Suspicion | 17 | Yes | 1.75 | 19.9 | 18.5 | B1 |
23 | CD3+CD4+CD26− | Yes | 2 | Yes | 27.91 | 51.1 | 89.5 | B2 |
24 | CD3+CD4+CD7−CD26− | Suspicion | Indirect | Yes | 1.3 | 23.7 | 23.8 | B1 |
25 | CD3+CD4+CD7−CD26− | No | None | Yes | 8.87 | 24.9 | 19.1 | B1 |
Abnormal cell phenotype identified by flow cytometry as phenotypically atypical: TCR-Vβ+ if >50% of the population of atypical cells express a single Vβ, or by indirect evidence, if there is <20% expression of the entire 27 Vβ antibody panel.44 PCR+ if ≥1 of 3 PCRs identifies a clone. B stage based on ISCL classification43 and the 2016 criteria proposed by Gibson et al.44 Patients staged as B2 have elevated absolute CD3+ or CD3+CD4+ cell counts, with the upper limits of normal defined as >2245 cells per microliter and >1612 cells per microliter, respectively. CD4+CD7− and CD4+CD26− percent specifications are defined as percentage of peripheral blood mononuclear cells (lymphocytes and monocytes).
N/A, not assessed; Pt ID, patient identifier.